Antibodies Produced by CLL Phenotype B Cells in Patients With Myasthenia Gravis Are Not Directed Against Neuromuscular Endplates
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 24, 2022
- Accepted in final form November 28, 2022
- First Published February 8, 2023.
Author Disclosures
- Florian Ingelfinger, PhD*,
- Michael Kramer, PhD*,
- Mirjam Lutz,
- Corinne C. Widmer, MD,
- Luca Piccoli, PhD,
- Stefanie Kreutmair, MD,
- Tobias Wertheimer, MD,
- Mark Woodhall, PhD,
- Patrick Waters, PhD,
- Federica Sallusto, PhD,
- Antonio Lanzavecchia, PhD,
- Sarah Mundt, PhD,
- Burkhard Becher, PhD† and
- Bettina Schreiner, MD†
- Florian Ingelfinger, PhD*,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Michael Kramer, PhD*,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Mirjam Lutz,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Corinne C. Widmer, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
HEM Pioneer - SAKK/Celgene Grant
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Luca Piccoli, PhD,
None
NONE
None
NONE
NONE
NONE
Vir Biotechnology Inc., Associate Director, 2.4 yearsVir Biotechnology Inc., Director, 0.3 yearsStock/Stock Options, Research Sponsor: Vir Biotechnology Inc., 2.7 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Stefanie Kreutmair, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Tobias Wertheimer, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Mark Woodhall, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Patrick Waters, PhD,
Vir Biotechnology Inc., Associate Director, 2.4 yearsVir Biotechnology Inc., Director, 0.3 yearsStock/Stock Options, Research Sponsor: Vir Biotechnology Inc., 2.7 years
NONE
Honoraria from UBC, UCB, Alexion and F. Hoffmann La-Roche.
Associate editor for Journal of Clinical Neurology
Assays for the detection of antibodies to LGI1, CASPR2, Tag-1 and GABA-A Receptor (g2 subunit).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
Patents for CASPR2, LGI1, TAG-1 and GABA-A Receptor (g2 subunit).
NONE
NONE
NONE
- Federica Sallusto, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Antonio Lanzavecchia, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Sarah Mundt, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Burkhard Becher, PhD† and
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Bettina Schreiner, MD†
Serving on an advisory board (Alexion Pharmaceuticals, Argenx)
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Schweizerische Stiftung zur Erforschung der Muskelkrankheiten(2) Betty & David Koetser Foundation for Brain Research(3) Olga Mayenfisch Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- From the Institute of Experimental Immunology (F.I., M.L., S.K., T.W., S.M., B.S., B.B.), University of Zurich, Switzerland; Department of Neurology (F.I., B.S.), University Hospital Zurich, Switzerland; Institute for Research in Biomedicine (M.K., L.P., F.S., A.L.), Università Della Svizzera Italiana, Bellinzona, Switzerland; Institute of Microbiology (M.K., F.S.), ETH Zurich, Switzerland; Department of Medical Oncology and Hematology (C.C.W.), University Hospital Zurich and University of Zurich, Switzerland; and Nuffield Department of Clinical Neurosciences (M.W., P.W.), University of Oxford, United Kingdom.
- Correspondence
Dr. Becher becher{at}immunology.uzh.ch or Dr. Schreiner bettina.schreiner{at}neuroimm.uzh.ch
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.